# Prognostic and Immunomodulatory Roles of BNIP3 in Osteosarcoma Revealed by Integrated Single‐Cell and Bulk Transcriptomic Profiling

**Authors:** Jiamiao Li, Wei Wang, Li Li, Kangjun Yu

PMC · DOI: 10.1155/ijog/9272264 · International Journal of Genomics · 2026-03-08

## TL;DR

This study identifies BNIP3 as a harmful gene in osteosarcoma, linked to poor survival and immune evasion, suggesting it could be a new therapeutic target.

## Contribution

The study reveals BNIP3 as a novel prognostic and immunomodulatory gene in osteosarcoma using integrated single-cell and bulk RNA sequencing.

## Key findings

- BNIP3 is the only significant prognostic gene associated with poor survival in osteosarcoma patients.
- High BNIP3 expression correlates with reduced immune cell infiltration and immune-related pathways.
- BNIP3-high patients show reduced sensitivity to potential therapeutic agents.

## Abstract

Osteosarcoma is a highly aggressive bone tumor with a complex tumor microenvironment (TME) that contributes to its progression and therapeutic resistance. In this study, we integrated single‐cell RNA sequencing (scRNA‐seq) and bulk RNA‐seq datasets to characterize the TME and identify key prognostic genes in osteosarcoma. Using scRNA‐seq data from 16 osteosarcoma samples, we defined eight major cell types within the TME and performed functional enrichment analyses. Through weighted gene co‐expression network analysis (WGCNA) focused on an inflammation‐related gene signature, we identified the yellow module as the most correlated with inflammation. By intersecting tumor‐upregulated genes with WGCNA‐derived genes, we identified BNIP3 as the only significant prognostic gene associated with poor survival in both the TARGET and GSE21257 cohorts. Functional annotation revealed that high BNIP3 expression is negatively correlated with immune‐related pathways and immune cell infiltration, including T cells, B cells, NK cells, and neutrophils. Additionally, BNIP3‐high patients exhibited a reduced sensitivity to several potential therapeutic agents. Our findings highlight BNIP3 as a hazardous gene in osteosarcoma, with important roles in immune evasion and prognosis, suggesting its potential as a therapeutic target.

## Linked entities

- **Genes:** BNIP3 (BCL2 interacting protein 3) [NCBI Gene 664]
- **Diseases:** osteosarcoma (MONDO:0002623)

## Full-text entities

- **Genes:** BNIP3 (BCL2 interacting protein 3) [NCBI Gene 664] {aka HABON, NIP3}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** gastric cancer (MESH:D013274), bone tumor (MESH:D001859), Osteosarcoma (MESH:D012516), Inflammation (MESH:D007249), epithelial and melanocytic tumors (MESH:D002277), Pan-Cancer (MESH:D009369), SKCM (MESH:C562393), BRCA (MESH:D001943), glioblastoma (MESH:D005909), colorectal cancer (MESH:D015179), metastasis (MESH:D009362)
- **Chemicals:** Navitoclax (MESH:C528561), cyclophosphamide (MESH:D003520), AGI-6780 (MESH:C581155), sepantronium bromide (MESH:C523798), ROS (MESH:D017382), Pevonedistat (MESH:C539933), GSK1904529A (MESH:C000607695)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968322/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968322/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968322/full.md

---
Source: https://tomesphere.com/paper/PMC12968322